Vyne Revenue and Competitors
Estimated Revenue & Valuation
- Vyne's estimated annual revenue is currently $6.4M per year.
- Vyne's estimated revenue per employee is $152,000
- Vyne's total funding is $15.5M.
Employee Data
- Vyne has 42 Employees.
- Vyne grew their employee count by -16% last year.
Vyne's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO & Co-founder | Reveal Email/Phone |
2 | Head Customer Success | Reveal Email/Phone |
3 | VP Revenue | Reveal Email/Phone |
4 | Finance Director | Reveal Email/Phone |
5 | Director Risk & Compliance | Reveal Email/Phone |
6 | Partnership & Integration Director | Reveal Email/Phone |
7 | Finance Manager | Reveal Email/Phone |
8 | AML Manager | Reveal Email/Phone |
9 | Risk and Compliance Manager, Deputy MLRO | Reveal Email/Phone |
10 | Commercial Manager - Account to account payments | Reveal Email/Phone |
Vyne Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $55.7M | 163 | -19% | N/A | N/A |
#2 | $12.5M | 59 | 7% | N/A | N/A |
#3 | $3.4M | 24 | 26% | N/A | N/A |
#4 | $16.2M | 77 | 28% | N/A | N/A |
#5 | $48M | 145 | -16% | N/A | N/A |
#6 | $85.1M | 324 | 19% | N/A | N/A |
#7 | $88.2M | 289 | 3% | N/A | N/A |
#8 | $411M | 1398 | 17% | N/A | N/A |
#9 | $105.3M | 401 | 55% | N/A | N/A |
#10 | $105.9M | 397 | 5% | $878.2M | N/A |
What Is Vyne?
vyne provides fast, efficient and secure bank to bank payments for Ecommerce apps and websites.
keywords:N/A
$15.5M
Total Funding
42
Number of Employees
$6.4M
Revenue (est)
-16%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Vyne News
2022-04-17 - -$0.15 EPS Expected for VYNE Therapeutics Inc. (NASDAQ ...
VYNE Therapeutics posted earnings per share of ($0.37) during the same quarter last year, which would suggest a positive year-over-year growth...
2022-04-17 - Zacks: Analysts Expect VYNE Therapeutics Inc. (NASDAQ ...
Zacks: Analysts Expect VYNE Therapeutics Inc. (NASDAQ:VYNE) Will Announce Quarterly Sales of $550,000.00. Posted by admin on Apr 22nd, 2022.
2022-04-06 - VYNE Therapeutics Announces Positive Phase 1b Efficacy ...
FMX114 is VYNE's proprietary investigational combination gel formulation of tofacitinib and fingolimod that is designed to address both the...
Other Companies in London
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $8.1M | 42 | 0% | N/A |
#2 | $1.7M | 42 | 11% | N/A |
#3 | $6.9M | 42 | 31% | N/A |
#4 | $8.4M | 42 | 0% | N/A |
#5 | $4.6M | 42 | 11% | N/A |